Continuing Education Activity

Verapamil, a non-dihydropyridine calcium channel blocker, plays a central role in the management of hypertension, angina, and supraventricular arrhythmias, and is also used off-label for conditions such as cluster headaches and hypertrophic cardiomyopathy. Verapamil’s dual actions on vascular smooth muscle relaxation and atrioventricular nodal conduction provide therapeutic benefit but necessitate careful attention to contraindications, drug interactions, and individualized dosing strategies. This activity provides clinicians with a comprehensive review of verapamil’s pharmacology, therapeutic applications, and safety considerations. Participants will gain practical knowledge to optimize prescribing, select appropriate formulations, and monitor for adverse effects, including bradycardia, hypotension, and atrioventricular block. Emphasis is placed on evidence-based therapy, recognition and management of toxicity, and interprofessional collaboration to enhance patient safety. By engaging in this activity, clinicians will strengthen their ability to deliver safe, effective, and personalized cardiovascular care with verapamil.

Objectives:

• Identify evidence-based indications and contraindications for verapamil use in patients with cardiovascular conditions.
• Evaluate potential drug-drug interactions involving verapamil and adjust therapy to minimize toxicity and therapeutic failure.
• Select appropriate verapamil formulations and dosing strategies based on patient-specific factors, including comorbidities and hepatic function.
• Collaborate with interprofessional team members to coordinate care, improve medication safety, and enhance patient outcomes during verapamil therapy.

Access free multiple choice questions on this topic.

Indications

FDA-Approved Indications

Verapamil is a non-dihydropyridine calcium channel blocker (CCB). The Food and Drug Administration (FDA) has approved the following indications for verapamil:

• Angina (chronic stable, vasospastic [Prinzmetal variant], and unstable angina [crescendo, preinfarction]) 
• Hypertension (as add-on therapy) 
• Paroxysmal supraventricular tachycardia (PSVT) prophylaxis
• Supraventricular tachycardia (SVT) [1]
• Atrial flutter and atrial fibrillation [2][3]
• According to the 2023 American Heart Association (AHA)/American College of Cardiology (ACC) guidelines, CCBs, including verapamil, are recommended as first-line antianginal therapy for patients with vasospastic angina.[4]
• Verapamil and trandolapril are available as fixed-dose (single-pill) combinations for the management of hypertension. However, according to the product label, this combination is not indicated for the initial treatment of hypertension.[5]

Off-Label Uses

Acute Coronary Syndrome

Verapamil may be given as an initial treatment in patients with (1) non-ST elevation acute coronary syndrome and (2) continuing or frequently recurring ischemia who are unable to use beta-blockers (eg, due to contraindications, unacceptable adverse effects, or insufficient response), in the absence of the following:

• Clinically significant left ventricular dysfunction
• Increased risk for cardiogenic shock
• PR interval greater than 0.24 seconds
• Second- or third-degree atrioventricular block without a cardiac pacemaker.

Furthermore, long-acting CCBs and nitrates are recommended for patients with coronary artery spasm, whereas short-acting calcium channel antagonists should be avoided.[6]

Cluster Headaches

Verapamil is recommended as a first-line prophylactic at a minimum dose of 240 mg/day to reduce headache severity and decrease the frequency of episodes during a cluster period.[7][8][9][10]

Hypertrophic Cardiomyopathy

Verapamil is recommended for the treatment of symptoms (eg, angina or dyspnea) in patients with obstructive or nonobstructive hypertrophic cardiomyopathy (HCM) who are unable to take beta-blockers (eg, due to adverse drug reactions, contraindications, or lack of response). Clinicians should consider the following.

• Verapamil should be initiated at a low dose and titrated up to 480 mg/day.
• Verapamil should be used with caution in patients with high gradients, advanced heart failure, or sinus bradycardia.[11][12][13]

Idiopathic Ventricular Tachycardia

Reports indicate that chronic oral verapamil therapy for verapamil-sensitive idiopathic left ventricular tachycardia can control idiopathic ventricular tachycardia in many adult and pediatric patients.[14]

Peyronie Disease

According to the American Urological Association guidelines, physicians may offer intralesional verapamil for Peyronie disease. Patients should receive counseling regarding potential adverse events, including pain at the injection site, dizziness, nausea, and penile bruising.[15]

Mechanism of Action

Verapamil is a non-dihydropyridine CCB. CCBs inhibit the entry of calcium ions into the slow L-type calcium channels in the myocardium and vascular smooth muscle during depolarization. This inhibition relaxes coronary vascular smooth muscle and induces vasodilation, benefiting patients with hypertension. Verapamil also increases myocardial oxygen delivery, thereby improving outcomes in patients with vasospastic angina. Verapamil produces negative chronotropic effects and reduces sympathetic nervous system activity.[16][17] In contrast, dihydropyridines bind to an extracellular region of the L-type calcium channel and preferentially inhibit vascular smooth muscle, leading to potent peripheral vasodilation with minimal direct cardiac suppression. This difference in tissue selectivity underlies the clinical divergence between the 2 classes: verapamil provides effective atrioventricular nodal blockade for arrhythmia management, whereas dihydropyridines primarily act as antihypertensive agents due to their strong vasodilatory effects (see Image. Simplified Mechanism of Action of Verapamil).[18] The primary objectives of rate management in patients with acute or chronic atrial fibrillation and rapid ventricular response are symptom control and prevention of left ventricular systolic dysfunction. Generally, non-dihydropyridine CCBs (diltiazem and verapamil) and beta-blockers are standard therapies for rate control in atrial fibrillation.[2]

Pharmacokinetics

Absorption: More than 90% of an orally administered dose of verapamil is absorbed. However, extensive first-pass hepatic metabolism during portal circulation reduces the absolute bioavailability to 20% to 35%. Peak plasma concentrations occur within 1 to 2 hours after immediate-release administration, whereas extended-release formulations reach peak concentrations after approximately 5 to 11 hours.

Distribution: Verapamil is approximately 90% bound to plasma proteins. After repeated dosing, verapamil and its principal active metabolite, norverapamil, are detectable in the cerebrospinal fluid at low concentrations.

Metabolism: Verapamil undergoes extensive hepatic metabolism, producing multiple metabolites. Norverapamil is the principal active metabolite and reaches plasma concentrations comparable to those of the parent drug. Hepatic impairment reduces metabolism, prolongs elimination half-life, increases volume of distribution, and decreases clearance. Verapamil is metabolized by cytochrome P450 3A (CYP3A4) and can interact with enzyme inducers or inhibitors.[19] Verapamil is also a P-glycoprotein (P-gp) inhibitor.[20][21]

Excretion: The elimination half-life of verapamil varies with formulation and patient factors. After a single oral dose of immediate-release verapamil, the half-life ranges from 2.8 to 7.4 hours. With multiple dosing, the half-life extends to 4.5 to 12 hours. Extended-release formulations have a half-life of approximately 12 hours. In patients with severe hepatic impairment, the elimination half-life may be prolonged to 14 to 16 hours. Verapamil is primarily excreted as metabolites, with approximately 70% of the dose eliminated in the urine and 16% or more in the feces. Only 3% to 4% of the drug is excreted unchanged in urine.

Administration

Available Dosage Forms and Strengths

Verapamil is available in multiple oral formulations, including immediate-release tablets (40, 80, and 120 mg) and extended-release tablets or 24-hour capsules in strengths ranging from 100 to 360 mg. These modified-release products differ in their pharmacokinetic profiles; controlled-release tablets and 24-hour capsules are designed to maintain more uniform plasma concentrations and reduce dosing frequency. Intravenous (IV) formulations are supplied as verapamil 2.5 mg/mL in 2- and 4-mL vials, including preservative-free options, for acute rate control when rapid onset is required. Sustained-release verapamil capsules may be opened, and the contents sprinkled on 1 tablespoon of applesauce. Patients should be instructed to swallow immediately with a full glass of cool water. Sustained-release verapamil products should be taken with food and swallowed whole (do not chew or crush). When administered intravenously, verapamil must be given over at least 2 minutes. 

Dosage

Hypertension

• For immediate-release formulations, the usual dosage range is 120 to 360 mg/day administered in 3 divided doses; the maximum dosage is 480 mg/day.[22]
• In geriatric patients, initiate therapy with lower doses and titrate to response.[23]

  • For immediate-release oral formulations, the initial dosage is 40 mg 3 times daily (TID).
  • For extended-release oral formulations, the initial dosage is 120 mg once daily in the morning or 100 mg once daily at bedtime.

Angina

• For oral dosing, immediate-release verapamil should be administered at 80 to 160 mg 3 times daily (TID).[24]

Atrial Fibrillation

• Intravenous [25]

  • Administer an initial bolus of 0.075 to 0.15 mg/kg over at least 2 minutes.
  • If the patient does not respond adequately, administer an additional 10 mg after 15 to 30 minutes.
  • If the patient responds adequately to the initial or repeat bolus dose, initiate continuous infusion.
• Oral [26]

  • For extended-release formulations, initiate a maintenance dosage of 180 to 480 mg once daily. 
  • For immediate-release formulations, initiate with 240 to 480 mg daily in 3 to 4 divided doses; the maximum daily dosage should be 480 mg/day.

Idiopathic Ventricular Tachycardia 

• Intravenous 

  • Administer 2.5 to 5.0 mg every 15 to 30 minutes.[27][28]
• Oral 

  • For immediate-release formulations, administer 360 mg/day in 3 divided doses.
  • For extended-release formulations, administer 240 to 480 mg once daily.[29][30]

Cluster Headaches

• Oral: For immediate-release formulations, administer 240 mg in 3 divided doses. If this dose does not produce an adequate response, increase the dose by 80 mg every 1 to 2 weeks until symptoms improve or adverse reactions occur.[31][32]

Paroxysmal Supraventricular Tachycardia Prophylaxis

• Oral: For immediate-release formulations, the usual dosage range is 240 to 480 mg in 3 to 4 divided doses.[33]

Ongoing Management of Supraventricular Tachycardia

• For immediate-release formulations, administer an initial dose of 120 mg in divided doses; the maximum maintenance dose is 480 mg/day. 

Acute Treatment of Supraventricular Tachycardia

Advanced Cardiovascular Life Support guidelines:

• Administer 2.5 to 5 mg over 2 minutes (over 3 minutes in geriatric patients). If the patient does not respond and has no adverse effects, a second dose of 5 to 10 mg (≈0.15 mg/kg) may be administered 15 to 30 minutes after the initial dose.[33]
• The maximum total dose is 20 to 30 mg.[34]

American College of Cardiology/American Heart Association/Heart Rhythm Society supraventricular tachycardia guidelines:

• Administer 5 to 10 mg (0.075 to 0.15 mg/kg) over 2 minutes.
• If the patient does not respond to this dose, a second dose may be given 30 minutes after the initial dose, followed by an infusion of 0.005 mg/kg/minute.[35]

Specific Patient Populations

Hepatic impairment: Verapamil is extensively metabolized by the liver and should be prescribed cautiously in patients with hepatic impairment. Dose reduction may be required. Clinicians should carefully monitor for PR interval prolongation.

Renal impairment: Clinicians should prescribe verapamil with caution in patients with end-stage renal disease, as the risk of adverse drug reactions may increase.[36]

Pregnancy considerations: Several important considerations apply to pregnant patients. Verapamil can cross the placenta.[37] Use during pregnancy may cause adverse effects on the fetus (eg, bradycardia, heart block, hypotension). Women with HCM controlled with verapamil before pregnancy may continue therapy; however, clinicians should monitor the fetus for bradycardia, hypotension, and heart block.[38] Verapamil may be used intravenously for the acute treatment of SVT in pregnant women when adenosine or beta-blockers are ineffective or contraindicated. Verapamil may also be used for the ongoing management of SVT in highly symptomatic patients; clinicians should use the lowest effective dose and avoid use during the first trimester if possible.[33] According to the American College of Obstetrics and Gynecology, if treatment for hypertension during pregnancy is needed, it is recommended to change to an alternative agent like nifedipine or labetalol.[39][40][41]

Breastfeeding considerations: Although verapamil is found in breast milk, the infant’s relative dose is less than or equal to 1% of the maternal dose adjusted for weight, which is below the relative infant dose (RID) threshold of 10%. Therefore, breastfeeding is generally considered safe with verapamil, although some manufacturers advise against it. Several case reports have assessed the RID in women taking 80 to 120 mg of verapamil 3 times daily within 3 months postpartum. No adverse events have been reported in breastfed infants.[42][43][44][45]

Pediatric patients: According to the 2025 Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list, verapamil should be used with caution in children younger than 1 year because of the risk of cardiovascular collapse.[46]

Older patients: Beta-blockers are an appropriate alternative to digoxin for rate control in atrial fibrillation. However, if the left ventricular ejection fraction is greater than 40%, nondihydropyridine CCBs (diltiazem and verapamil) can also be used with caution.[47] However, verapamil is listed in the American Geriatrics Society (AGS) Beers Criteria as a medication to avoid in older adults with heart failure with reduced ejection fraction. Verapamil produces a clinically significant negative inotropic effect, and this reduction in myocardial contractility can exacerbate systolic dysfunction and precipitate decompensated heart failure.[48] If verapamil is necessary for therapy in older adults, clinicians should initiate therapy at a low dose after screening for renal and hepatic impairment. Clinicians should also consider polypharmacy and drug-drug interactions.

Adverse Effects

Adverse Effects

Adverse effects reported with verapamil therapy include:

• Fatigue
• Dyspepsia
• Gingival hyperplasia [49] 
• Constipation [50]
• Hypotension [36] 
• Peripheral edema [51]

Drug-Drug Interactions

Cytochrome P450–mediated interactions: Verapamil is extensively metabolized by CYP3A4, and CYP3A4 inhibitors such as erythromycin or ritonavir increase its plasma concentration by reducing hepatic clearance. This elevation raises the risk of bradycardia, hypotension, and atrioventricular block; clinicians should lower the verapamil dose or avoid the combination. CYP3A4 inducers, such as rifampin, markedly reduce verapamil exposure by accelerating its metabolism, which can lead to therapeutic failure. Clinicians should avoid the combination or anticipate the need for higher doses.[52] Grapefruit juice inhibits intestinal CYP3A4 and consequently increases oral verapamil bioavailability; therefore, patients receiving oral verapamil formulations should avoid grapefruit products to prevent excessive drug levels.

P-glycoprotein–mediated interactions: Verapamil moderately inhibits P-gp, which can increase blood levels of P-gp substrates and raise the risk of toxicity. For example, verapamil increases digoxin concentrations, necessitating dose adjustment. Verapamil also elevates systemic levels of dabigatran and colchicine.[53][54] In addition, verapamil may increase blood levels of immunosuppressants such as cyclosporine and tacrolimus, necessitating frequent therapeutic drug monitoring.[55] By inhibiting P-gp at the blood-brain barrier, verapamil enhances the central nervous system effects of medications such as loperamide.[56] Clinicians should monitor for adverse reactions and adjust dosages as needed when these agents are coadministered with verapamil.

Beta-blockers: Beta-blockers and verapamil both depress atrioventricular nodal conduction and myocardial contractility. Their combination increases the likelihood of bradycardia, heart block, or acute decompensated heart failure; clinicians should prescribe them together only with a clear indication and close monitoring, particularly in patients with conduction disease or left ventricular dysfunction. Even topical ophthalmic beta-blockers such as timolol can interact, because systemic absorption is sufficient to produce additive atrioventricular nodal suppression.[57]

Clonidine: Clonidine reduces sympathetic outflow, and verapamil depresses atrioventricular nodal conduction. Their combination can cause bradycardia; therefore, heart rate monitoring is essential.[58]

Statins: Verapamil inhibits CYP3A4-mediated metabolism of simvastatin, lovastatin, and atorvastatin, which raises statin concentrations and increases the risk of myopathy or rhabdomyolysis. Dose restrictions (simvastatin ≤10 mg/day, lovastatin ≤40 mg/day) or use of alternative statins are therefore recommended.

Alcohol: Verapamil slows gastric emptying and reduces hepatic metabolism of ethanol, prolonging elevated blood alcohol concentrations. Patients should be counseled accordingly.

Ivabradine: Verapamil increases ivabradine exposure through CYP3A4 inhibition and additive negative chronotropy. This interaction can lead to profound bradycardia; therefore, the combination should be avoided.

Theophylline: Verapamil reduces theophylline clearance, increasing the risk of toxic theophylline levels; clinicians should monitor for tremor, tachyarrhythmias, or gastrointestinal upset.

Antihypertensives: Verapamil adds to the vasodilatory or negative chronotropic effects of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, and alpha-blockers. The combined regimen can produce symptomatic hypotension; therefore, blood pressure should be monitored during initiation and titration.

Antiarrhythmic agents: Disopyramide has potent negative inotropic effects, and verapamil further depresses contractility. The 2 agents should not be administered within 48 hours of each other to avoid acute heart failure or severe hypotension. Flecainide slows conduction through the His-Purkinje system, and verapamil slows atrioventricular nodal conduction. Their combination can produce additive conduction delay and bradycardia; therefore, electrocardiographic monitoring and symptom assessment are essential if used together. Quinidine causes peripheral vasodilation, and verapamil adds vasodilatory and negative inotropic effects; therefore, patients with hypertrophic cardiomyopathy may experience severe hypotension. Clinicians should generally avoid this combination.[59]

Nitrates: Nitrates and verapamil both cause vasodilation, but their mechanisms are complementary and generally well tolerated. The combination is commonly used in angina without clinically significant adverse interaction.

Phenobarbital: Phenobarbital induces hepatic enzymes and increases verapamil clearance, reducing verapamil effectiveness. Dose adjustments may be required.

Carbamazepine: Verapamil inhibits carbamazepine metabolism, increasing carbamazepine levels and potentially causing symptoms such as diplopia, ataxia, or dizziness. Dose reduction is often necessary.[60][61]

Cyclosporine: Verapamil inhibits cyclosporine metabolism, increasing serum concentrations and the risk of nephrotoxicity. Cyclosporine levels should be monitored and doses adjusted accordingly.[62]

Inhalation anesthetics: Inhalation anesthetics depress calcium-dependent myocardial contraction, and verapamil reduces calcium influx. Their combined effects can cause exaggerated hypotension or bradycardia during surgery; therefore, anesthetic dosing should be carefully titrated.[63]

Mammalian target of rapamycin inhibitors: Verapamil inhibits CYP3A4 and increases exposure to sirolimus and everolimus.[64] Mammalian target of rapamycin inhibitors can also increase verapamil levels; therefore, dose reductions for both agents should be considered to avoid toxicity.

Telithromycin: Telithromycin can cause bradyarrhythmias and hypotension on its own, and verapamil can enhance these effects through CYP3A4 inhibition and additive conduction slowing. The combination should be avoided.[65]

Neuromuscular blocking drugs: Verapamil potentiates neuromuscular blockers by reducing calcium-dependent acetylcholine release, thereby prolonging paralysis; anesthesiologists should reduce neuromuscular blocking agent dosing and monitor recovery.[66]

Contraindications

Oral Formulation

The oral formulation of verapamil is contraindicated in the following conditions:

• Hypersensitivity to verapamil or any component of the verapamil formulation (immediate-release or extended-release).
• Severe dysfunction of the left ventricle.
• Severe hypotension, defined as a systolic blood pressure of less than 90 mm Hg, or cardiogenic shock (except in patients with a functioning artificial ventricular pacemaker)
• Sick sinus syndrome and second- or third-degree atrioventricular block [67] (except in patients with a functioning artificial ventricular pacemaker).
• Atrial flutter or fibrillation associated with an accessory bypass tract (eg, Lown-Ganong-Levine syndrome or Wolff-Parkinson-White syndrome).

Intravenous Formulation

The IV formulation of verapamil is contraindicated in the following conditions:

• Severe heart failure (unless the heart failure results from an SVT responsive to verapamil).
• Concomitant use of IV beta-blockers.

Warnings and Precautions

• Verapamil may cause first-degree atrioventricular block, and higher degrees of atrioventricular block can occur in patients with sick sinus syndrome. Clinicians should consider dosage reduction or discontinuation of verapamil therapy.[34]
• Verapamil is contraindicated in patients with wide complex tachycardias unless proven to be supraventricular in origin. Severe hypotension may occur upon administration.[68]
• Verapamil should be avoided in patients with heart failure, particularly those with reduced ejection fraction, because CCBs confer greater risk than benefit in this population.[38]
• Verapamil should be used with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction, including those with

  • high gradients
  • advanced heart failure [69]
  • sinus bradycardia
• Verapamil should not be used in patients with HCM and systemic hypotension or severe dyspnea at rest.[70]

Monitoring

Clinicians should monitor blood pressure, heart rate, and liver function tests in patients receiving verapamil. An electrocardiogram should be obtained to assess the PR interval and rule out atrioventricular block before initiating verapamil.[71] 

Goals of Therapy

• Blood pressure is an essential indicator of therapeutic response in patients with confirmed hypertension receiving verapamil. A patient’s atherosclerotic cardiovascular disease (ASCVD) risk and comorbidities should be evaluated to determine the specific blood pressure goal.
• For patients with confirmed hypertension and known cardiovascular disease or a 10-year ASCVD risk greater than or equal to 10%, the recommended target blood pressure is less than 130/80 mm Hg. For patients without markers of increased ASCVD risk, a target blood pressure below 130/80 mm Hg is not a formal recommendation but may be considered a reasonable goal.[72]

Special Populations

• Renal impairment: If repeated IV injections are necessary for therapy, clinicians should monitor blood pressure and PR interval readings.
• Liver impairment (cirrhosis): According to an older pharmacokinetic study, electrocardiogram monitoring should be performed, and the dose may be reduced to

  • 20% for oral formulations
  • 50% for IV formulations [73]

These dose reductions are simplified guides; comorbidities, concomitant medications, and disease pathophysiology should always be considered when adjusting therapy.

Toxicity

Signs and Symptoms of Overdose

Like other CCBs, verapamil overdose can produce negative inotropic and chronotropic effects, arterial vasodilation, and hypotension. Additionally, verapamil blocks slow calcium channels in pancreatic beta cells, inhibiting insulin release and causing hyperglycemia. Bradycardia accompanied by hypotension, metabolic acidosis, and hyperglycemia is indicative of verapamil toxicity. The most serious complications of verapamil overdose are bradycardia and hypotension, both of which can be fatal if untreated.[74]

If a patient presents with verapamil toxicity within 1 hour of ingestion, decontamination options include gastric lavage and single-dose activated charcoal.[75][76] If presentation occurs more than 1 hour after ingestion, whole bowel irrigation with polyethylene glycol electrolyte solution is a viable decontamination method. Experimental and clinical studies indicate that ipecac and cathartics are not beneficial for decontamination.[77][78][79]

Management of Overdose

Symptomatic patients should undergo treatment, with priority given to first-line therapy. The choice of first-line therapy depends on the desired clinical effect and may include:[80]

• IV calcium
• High-dose insulin monotherapy (for patients with myocardial dysfunction)
• Norepinephrine or epinephrine for patients in shock (norepinephrine is preferred in vasodilatory shock).

Patients refractory to first-line therapies may require the following interventions:

• Fat emulsion therapy
• Incremental doses of high-dose insulin in patients with myocardial dysfunction
• Pacemaker placement in patients with unstable bradycardia or high-grade atrioventricular block without significant alteration in cardiac inotropy.

Patients with refractory shock or pre-cardiac arrest may require the following interventions:  

• Incremental doses of high-dose insulin
• Fat emulsion therapy[81]
• Venoarterial extracorporeal membrane oxygenation (VA-ECMO), reserved for refractory shock with a significant cardiogenic component.[82]

Administration of calcium chloride or calcium gluconate in symptomatic patients represents another therapeutic option.[36] Calcium chloride is preferred in nonacidotic patients because it delivers 3 times more calcium than calcium gluconate. In contrast, calcium gluconate is preferred in acidotic patients because calcium chloride may worsen acidosis. Both calcium formulations are administered intravenously. Extravasation is a potential risk associated with IV calcium administration.[83][84]

Enhancing Healthcare Team Outcomes

Healthcare professionals, including pharmacists, nurses, advanced practice providers, and physicians, who prescribe and dispense verapamil should be aware of adverse drug reactions and sound-alike/look-alike issues among brand names and formulations. These concerns necessitate monitoring of heart rate and blood pressure.[85][86]

Pharmacists should educate patients about verapamil’s adverse drug reactions, how to recognize them, and appropriate actions if they occur. Pharmacists should also review the patient’s medication regimen to identify and prevent drug-drug interactions. Pharmacists should educate physicians and nurses on the differences between oral and IV dosing and exercise caution when converting between routes of administration.

When switching from an oral to an IV formulation, the total daily dose of verapamil should remain the same unless formulation strength prevents a direct milligram-for-milligram conversion. Therefore, nurses and clinicians should consult pharmacists when prescribing or counseling on dosing and administration of verapamil formulations, and nurses should incorporate this information into patient counseling.[87] Participants managed through the Pharmacist-Physician Collaborative Practice Model achieved blood pressure targets more rapidly and were more likely to remain controlled than those in usual care, owing to reduced therapeutic inertia and more intensive early follow-up.[88]

A shared clinical dashboard provides a unified, real-time display of key parameters relevant to verapamil therapy, including heart rate, blood pressure, PR interval measurements, recent dose adjustments, and concomitant medications.[89] When all healthcare professionals reference the same structured dataset rather than dispersed documentation, titration becomes more consistent, communication is simplified, and early detection of bradycardia, hypotension, or emerging drug-drug interactions is enhanced. An interprofessional team approach and effective communication among physicians, advanced practice providers, pharmacists, and nurses are essential for minimizing adverse effects and optimizing patient outcomes with verapamil therapy.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Chevalier C, Fischer L. Conversion of sustained supraventricular tachycardia into sinus rhythm after stellate ganglion block: A case report and pathophysiological considerations. J Int Med Res. 2025 Aug;53(8):3000605251363527. [PMC free article: PMC12340340] [PubMed: 40787915]

2.

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR., Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 02;149(1):e1-e156. [PMC free article: PMC11095842] [PubMed: 38033089]

3.

Baba Y, Kubo T, Kawada K, Ochi Y, Hirota T, Yamasaki N, Kitaoka H. Intravenous Verapamil for the Management of Atrial Fibrillation: The Gap Between the Guidelines and Clinical Practice. Intern Med. 2025 Oct 15;64(20):2944-2952. [PMC free article: PMC12589163] [PubMed: 40222944]

4.

Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS., Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. [PubMed: 37471501]

5.

Zou Z, Xu FY, Wang L, An MM, Zhang H, Shi XY. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2011 Mar;25(3):203-10. [PubMed: 20535140]

6.

Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228. [PubMed: 25260718]

7.

Weaver-Agostoni J. Cluster headache. Am Fam Physician. 2013 Jul 15;88(2):122-8. [PubMed: 23939643]

8.

Koppen H, Stolwijk J, Wilms EB, van Driel V, Ferrari MD, Haan J. Cardiac monitoring of high-dose verapamil in cluster headache: An international Delphi study. Cephalalgia. 2016 Dec;36(14):1385-1388. [PubMed: 26868817]

9.

Brandt RB, Mulleners WM, Couturier E, Carpay JA, Gerlach OHH, Niesters M, Haan J, van Zwet EW, Ferrari MD, Fronczek R. Greater occipital nerve injection with methylprednisolone as transitional therapy in episodic cluster headache: Results from an RCT. Cephalalgia. 2025 Sep;45(9):3331024251370324. [PubMed: 40990636]

10.

Wu Y, Zhang M, Dong Z, Yu S. Case report: Prophylactic administration of verapamil for cluster headache during the pre-episode symptoms phase. Headache. 2025 Sep;65(8):1492-1494. [PubMed: 40985119]

11.

American College of Cardiology Foundation/American Heart Association Task Force on Practice. American Association for Thoracic Surgery. American Society of Echocardiography. American Society of Nuclear Cardiology. Heart Failure Society of America. Heart Rhythm Society. Society for Cardiovascular Angiography and Interventions. Society of Thoracic Surgeons. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2011 Dec;142(6):e153-203. [PubMed: 22093723]

12.

Awad K, Pereyra Pietri M, Farina JM, Pathangey G, Abbas MT, Scalia IG, Le Couteur D, Wilanksy S, Lester SJ, Ommen SR, Geske JB, Arsanjani R, Ayoub C. Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):469-482. [PMC free article: PMC12343041] [PubMed: 40377024]

13.

Aimo A, Todiere G, Barison A, Tomasoni D, Panichella G, Masri A, Maron MS. Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines. Heart Fail Rev. 2025 Mar;30(2):315-325. [PubMed: 39520615]

14.

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018 Oct;15(10):e190-e252. [PubMed: 29097320]

15.

Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, Khera M, Kirkby E, McVary KT, Miner MM, Nelson CJ, Sadeghi-Nejad H, Seftel AD, Shindel AW, Burnett AL., American Urological Association Education and Research, Inc., Peyronie's Disease: AUA Guideline. J Urol. 2015 Sep;194(3):745-53. [PMC free article: PMC5027990] [PubMed: 26066402]

16.

Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich). 2004 Nov;6(11):621-29; quiz 630-1. [PMC free article: PMC8109670] [PubMed: 15538095]

17.

Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol. 2000 Dec;15(3-4):302-16. [PubMed: 11149130]

18.

Bird GS, D'Agostin D, Alsanosi S, Lip S, Padmanabhan S, Parekh AB. A Reappraisal of the Effects of L-type Ca²⁺ Channel Blockers on Store-Operated Ca²⁺ Entry and Heart Failure. Function (Oxf). 2023;4(6):zqad047. [PMC free article: PMC10568199] [PubMed: 37841523]

19.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 11, 2017. Verapamil. [PMC free article: PMC547852] [PubMed: 31643683]

20.

Hunt TL, Tzanis E, Bai S, Manley A, Chitra S, McGovern PC. The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study. Eur J Drug Metab Pharmacokinet. 2021 Jan;46(1):85-92. [PMC free article: PMC7811981] [PubMed: 33180250]

21.

Zahir H, Murai M, Wu L, Valentine M, Hynes S. Clinical Assessment of the Drug-Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants. J Clin Pharmacol. 2025 Jun;65(6):715-730. [PMC free article: PMC12110731] [PubMed: 39920097]

22.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. [PubMed: 29133356]

23.

Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA., ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31;123(21):2434-506. [PubMed: 21518977]

24.

Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB, Fihn SD, Fraker TD, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV., American College of Cardiology. American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003 Jan 01;41(1):159-68. [PubMed: 12570960]

25.

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW., ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 02;130(23):e199-267. [PMC free article: PMC4676081] [PubMed: 24682347]

26.

Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 1997 Nov-Dec;17(6):1238-45. [PubMed: 9399606]

27.

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-e391. [PubMed: 29084731]

28.

Gill JS, Blaszyk K, Ward DE, Camm AJ. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J. 1993 Nov;126(5):1126-33. [PubMed: 8237755]

29.

Gill JS, Mehta D, Ward DE, Camm AJ. Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br Heart J. 1992 Oct;68(4):392-7. [PMC free article: PMC1025139] [PubMed: 1449923]

30.

Gill JS, Ward DE, Camm AJ. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992 Nov;15(11 Pt 2):2122-6. [PubMed: 1279611]

31.

May A, Leone M, Afra J, Linde M, Sándor PS, Evers S, Goadsby PJ., EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006 Oct;13(10):1066-77. [PubMed: 16987158]

32.

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016 Jul;56(7):1093-106. [PubMed: 27432623]

33.

Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NAM, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016 Apr 05;67(13):e27-e115. [PubMed: 26409259]

34.

Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010 Nov 02;122(18 Suppl 3):S729-67. [PubMed: 20956224]

35.

Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NA, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM., Evidence Review Committee Chair‡ 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016 Apr 05;133(14):e506-74. [PubMed: 26399663]

36.

Kaisbain N, Lim WJ, Kaisbain V. Verapamil-Induced Hypotension in End-Stage Renal Disease: The Role of Calcium Gluconate. Cureus. 2023 Jan;15(1):e33341. [PMC free article: PMC9896430] [PubMed: 36741660]

37.

Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J. 2001 Mar;22(6):458-64. [PubMed: 11237540]

38.

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW., American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. American Association for Thoracic Surgery. American Society of Echocardiography. American Society of Nuclear Cardiology. Heart Failure Society of America. Heart Rhythm Society. Society for Cardiovascular Angiography and Interventions. Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 Dec 13;124(24):e783-831. [PubMed: 22068434]

39.

Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. [PubMed: 24150027]

40.

Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson K, Haas DM, Plante L, Metz T, Casey B, Esplin S, Longo S, Hoffman M, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su E, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Oparil S, Cutter GR, Andrews WW., Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022 May 12;386(19):1781-1792. [PMC free article: PMC9575330] [PubMed: 35363951]

41.

Leonard SA, Siadat S, Huybrechts KF, Main EK, Hlatky MA, Hernández-Díaz S, Bateman BT. Comparative Effectiveness and Safety of Labetalol Versus Nifedipine for Treatment of Chronic Hypertension During Pregnancy. JACC Adv. 2025 Sep;4(9):102054. [PMC free article: PMC12539438] [PubMed: 40772922]

42.

Andersen HJ. Excretion of verapamil in human milk. Eur J Clin Pharmacol. 1983;25(2):279-80. [PubMed: 6628513]

43.

Anderson P, Bondesson U, Mattiasson I, Johansson BW. Verapamil and norverapamil in plasma and breast milk during breast feeding. Eur J Clin Pharmacol. 1987;31(5):625-7. [PubMed: 3830249]

44.

Inoue H, Unno N, Ou MC, Iwama Y, Sugimoto T. Level of verapamil in human milk. Eur J Clin Pharmacol. 1984;26(5):657-8. [PubMed: 6468488]

45.

Miller MR, Withers R, Bhamra R, Holt DW. Verapamil and breast-feeding. Eur J Clin Pharmacol. 1986;30(1):125-6. [PubMed: 3709626]

46.

McPherson C, Meyers RS, Thackray J, Stutzman DL, Mills KP, Said SJ, Patel K, Hellinga RC, Potts AL, Lubsch L, Matson KL, Hoff DS. Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics. J Pediatr Pharmacol Ther. 2025 Aug;30(4):422-439. [PMC free article: PMC12351480] [PubMed: 40821415]

47.

American Geriatrics Society Beers Criteria® Alternatives Panel. Steinman MA. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®. J Am Geriatr Soc. 2025 Sep;73(9):2657-2677. [PMC free article: PMC12448428] [PubMed: 40697073]

48.

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PMC free article: PMC12478568] [PubMed: 37139824]

49.

Matharu MS, van Vliet JA, Ferrari MD, Goadsby PJ. Verapamil induced gingival enlargement in cluster headache. J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):124-7. [PMC free article: PMC1739323] [PubMed: 15608012]

50.

White WB, Johnson MF, Anders RJ, Elliott WJ, Black HR. Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. Am Heart J. 2001 Dec;142(6):1010-5. [PubMed: 11717605]

51.

Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8(6):357-73. [PubMed: 17154643]

52.

Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66. [PubMed: 14744949]

53.

Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013 Apr;75(4):1053-62. [PMC free article: PMC3612723] [PubMed: 22946890]

54.

Hendrikse NH. Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des. 2000 Nov;6(16):1653-68. [PubMed: 10974159]

55.

Muzi M, Mankoff DA, Link JM, Shoner S, Collier AC, Sasongko L, Unadkat JD. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med. 2009 Aug;50(8):1267-75. [PMC free article: PMC2754733] [PubMed: 19617341]

56.

Lubberink M. Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography. Curr Pharm Des. 2016;22(38):5786-5792. [PubMed: 27494063]

57.

Richards TR, Tobe SW. Combining other antihypertensive drugs with β-blockers in hypertension: a focus on safety and tolerability. Can J Cardiol. 2014 May;30(5 Suppl):S42-6. [PubMed: 24518661]

58.

Jaffe R, Livshits T, Bursztyn M. Adverse interaction between clonidine and verapamil. Ann Pharmacother. 1994 Jul-Aug;28(7-8):881-3. [PubMed: 7949506]

59.

Trohman RG, Estes DM, Castellanos A, Palomo AR, Myerburg RJ, Kessler KM. Increased quinidine plasma concentrations during administration of verapamil: a new quinidine-verapamil interaction. Am J Cardiol. 1986 Mar 01;57(8):706-7. [PubMed: 3953464]

60.

Tan MH, Yee SY, Yahya R. Lessons of the month 2: A case of inappropriate drug-drug interaction in kidney transplant. Clin Med (Lond). 2022 Mar;22(2):169-171. [PMC free article: PMC8966831] [PubMed: 35304379]

61.

Macphee GJ, McInnes GT, Thompson GG, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet. 1986 Mar 29;1(8483):700-3. [PubMed: 2870222]

62.

Tolou-Ghamari Z. Tacrolimus and Cyclosporin Pharmacotherapy, Detection Methods, Cytochrome P450 Enzymes after Heart Transplantation. Cardiovasc Hematol Agents Med Chem. 2024;22(2):106-113. [PubMed: 37496131]

63.

Zuck D, Rao JJ. Profound bradycardia with verapamil and halothane. Anaesthesia. 1985 Jan;40(1):84-5. [PubMed: 3970347]

64.

Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol. 2005 Oct;60(4):434-7. [PMC free article: PMC1884822] [PubMed: 16187976]

65.

Reed M, Wall GC, Shah NP, Heun JM, Hicklin GA. Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60. [PubMed: 15598962]

66.

Nagaral J, Gh S, K J, Kumar K S, Gs J, Pk C, Patil R. Study on neuromuscular blockade action of verapamil in albino rats. J Clin Diagn Res. 2013 Aug;7(8):1617-9. [PMC free article: PMC3782912] [PubMed: 24086855]

67.

Lopes D, Teixeira B, Rocha V, Santos MG, Monteiro E. Continuous Intra-arterial Infusion of Verapamil for Severe Vasospasm Treatment After Subarachnoid Hemorrhage: A Case Report. Cureus. 2025 Apr;17(4):e82561. [PMC free article: PMC12086603] [PubMed: 40390753]

68.

WRITING COMMITTEE MEMBERS. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL., American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327. [PubMed: 23741058]

69.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 03;79(17):e263-e421. [PubMed: 35379503]

70.

Nishimura RA, Holmes DR. Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004 Mar 25;350(13):1320-7. [PubMed: 15044643]

71.

Ekhlaspour L, Buckingham B, Bauza C, Clements M, Forlenza GP, Neyman A, Norlander L, Schamberger M, Sherr JL, Bailey R, Beck RW, Kollman C, Beasley S, Cobry E, DiMeglio LA, Paprocki E, Van Name M, Moran A., CLVer Study Group. Safety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer experience. J Clin Transl Endocrinol. 2024 Jun;36:100352. [PMC free article: PMC11163172] [PubMed: 38860154]

72.

Aleyadeh W, Hutt-Centeno E, Ahmed HM, Shah NP. Hypertension guidelines: Treat patients, not numbers. Cleve Clin J Med. 2019 Jan;86(1):47-56. [PubMed: 30624184]

73.

Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol. 1981 Jul;12(1):51-60. [PMC free article: PMC1401748] [PubMed: 7248141]

74.

Isbister GK, Jenkins S, Harris K, Downes MA, Isoardi KZ. Calcium channel blocker overdose: Not all the same toxicity. Br J Clin Pharmacol. 2025 Mar;91(3):740-747. [PMC free article: PMC11862784] [PubMed: 39305202]

75.

Benson BE, Hoppu K, Troutman WG, Bedry R, Erdman A, Höjer J, Mégarbane B, Thanacoody R, Caravati EM., American Academy of Clinical Toxicology. European Association of Poisons Centres and Clinical Toxicologists. Position paper update: gastric lavage for gastrointestinal decontamination. Clin Toxicol (Phila). 2013 Mar;51(3):140-6. [PubMed: 23418938]

76.

Chyka PA, Seger D, Krenzelok EP, Vale JA., American Academy of Clinical Toxicology. European Association of Poisons Centres and Clinical Toxicologists. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila). 2005;43(2):61-87. [PubMed: 15822758]

77.

Thanacoody R, Caravati EM, Troutman B, Höjer J, Benson B, Hoppu K, Erdman A, Bedry R, Mégarbane B. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila). 2015 Jan;53(1):5-12. [PubMed: 25511637]

78.

American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Pediatrics. 2003 Nov;112(5):1182-5. [PubMed: 14595067]

79.

Höjer J, Troutman WG, Hoppu K, Erdman A, Benson BE, Mégarbane B, Thanacoody R, Bedry R, Caravati EM., American Academy of Clinical Toxicology. European Association of Poison Centres and Clinical Toxicologists. Position paper update: ipecac syrup for gastrointestinal decontamination. Clin Toxicol (Phila). 2013 Mar;51(3):134-9. [PubMed: 23406298]

80.

St-Onge M, Anseeuw K, Cantrell FL, Gilchrist IC, Hantson P, Bailey B, Lavergne V, Gosselin S, Kerns W, Laliberté M, Lavonas EJ, Juurlink DN, Muscedere J, Yang CC, Sinuff T, Rieder M, Mégarbane B. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. Crit Care Med. 2017 Mar;45(3):e306-e315. [PMC free article: PMC5312725] [PubMed: 27749343]

81.

Sampson CS, Bedy SM. Lipid emulsion therapy given intraosseously in massive verapamil overdose. Am J Emerg Med. 2015 Dec;33(12):1844.e1. [PubMed: 26003744]

82.

Slamowitz A, Sweberg T, Labgold K, Nickerson T. Extracorporeal Membrane Oxygenation for Calcium Channel Blocker Intoxication: A Multicenter Retrospective Registry Review. ASAIO J. 2025 Oct 31; [PubMed: 41168146]

83.

Lin CY, Hsieh KC, Yeh MC, Sheen-Chen SM, Chou FF. Skin necrosis after intravenous calcium chloride administration as a complication of parathyroidectomy for secondary hyperparathyroidism: report of four cases. Surg Today. 2007;37(9):778-81. [PubMed: 17713732]

84.

Pacheco Compaña FJ, Midón Míguez J, de Toro Santos FJ. Lesions Associated With Calcium Gluconate Extravasation: Presentation of 5 Clinical Cases and Analysis of Cases Published. Ann Plast Surg. 2017 Nov;79(5):444-449. [PubMed: 28570460]

85.

Michaels AD, Spinler SA, Leeper B, Ohman EM, Alexander KP, Newby LK, Ay H, Gibler WB., American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Council on Quality of Care and Outcomes Research. Council on Cardiopulmonary, Critical Care, Perioperative, and Resuscitation. Council on Cardiovascular Nursing. Stroke Council. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation. 2010 Apr 13;121(14):1664-82. [PubMed: 20308619]

86.

Whitaker M, Lester C, Rowell B. Handing Off Electronic Prescription Data From Prescribers to Community Pharmacies: A Qualitative Analysis of Pharmacy Staff Perspectives. J Patient Saf. 2024 Sep 01;20(6):397-403. [PMC free article: PMC11335435] [PubMed: 38742931]

87.

Townley JN, Pogue CA, McHugh MD. Criminal prosecution of clinician errors: A setback to the progress toward safe hospital work environments. J Hosp Med. 2022 Oct;17(10):850-853. [PMC free article: PMC9720757] [PubMed: 36031735]

88.

Dixon DL, Sisson EM, Parod ED, Van Tassell BW, Nadpara PA, Carl D, W Dow A. Pharmacist-physician collaborative care model and time to goal blood pressure in the uninsured population. J Clin Hypertens (Greenwich). 2018 Jan;20(1):88-95. [PMC free article: PMC8031164] [PubMed: 29237095]

89.

Fitzpatrick C, Kantoris C, Giavatto C, Lopez-Medina AI, Mourani J, Hardin B, Mayol Torres H, Skrtic A, Rosa E. Clinical dashboard development and implementation to standardize data capture and reporting across health-system specialty pharmacies. Am J Health Syst Pharm. 2024 Jun 24;81(13):e379-e385. [PubMed: 38375599]

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.